These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 15329307)
1. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Bramon E; Rabe-Hesketh S; Sham P; Murray RM; Frangou S Schizophr Res; 2004 Oct; 70(2-3):315-29. PubMed ID: 15329307 [TBL] [Abstract][Full Text] [Related]
2. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Bramon E; McDonald C; Croft RJ; Landau S; Filbey F; Gruzelier JH; Sham PC; Frangou S; Murray RM Neuroimage; 2005 Oct; 27(4):960-8. PubMed ID: 16009570 [TBL] [Abstract][Full Text] [Related]
3. P300 waveform and dopamine transporter availability: a controlled EEG and SPECT study in medication-naive patients with schizophrenia and a meta-analysis. Chen KC; Lee IH; Yang YK; Landau S; Chang WH; Chen PS; Lu RB; David AS; Bramon E Psychol Med; 2014 Jul; 44(10):2151-62. PubMed ID: 24238542 [TBL] [Abstract][Full Text] [Related]
4. P300 aberration in first-episode schizophrenia patients: a meta-analysis. Qiu YQ; Tang YX; Chan RC; Sun XY; He J PLoS One; 2014; 9(6):e97794. PubMed ID: 24933577 [TBL] [Abstract][Full Text] [Related]
6. State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia. Mori K; Morita K; Shoji Y; Matsuoka T; Fujiki R; Uchimura N Psychiatry Clin Neurosci; 2012 Jun; 66(4):261-9. PubMed ID: 22624730 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of studies in China about changes in P300 latency and amplitude that occur in patients with schizophrenia during treatment with antipsychotic medication. Su L; Cai Y; Shi S; Wang L Shanghai Arch Psychiatry; 2012 Aug; 24(4):200-7. PubMed ID: 25324627 [TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine on auditory P300 in schizophrenia. Gonul AS; Suer C; Coburn K; Ozesmi C; Oguz A; Yilmaz A Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):173-7. PubMed ID: 12551741 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Jeon YW; Polich J Psychophysiology; 2003 Sep; 40(5):684-701. PubMed ID: 14696723 [TBL] [Abstract][Full Text] [Related]
10. P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication. Coburn KL; Shillcutt SD; Tucker KA; Estes KM; Brin FB; Merai P; Moore NC Biol Psychiatry; 1998 Sep; 44(6):466-74. PubMed ID: 9777178 [TBL] [Abstract][Full Text] [Related]
11. [Evoked potentials N200/P300 disorders and clinical phenotype in Cuban families with paranoid schizophrenia: a family-based association study]. Guerra López S; Martín Reyes M; Pedroso Rodríguez Mde L; Reyes Berazain A; Mendoza Quiñones R; Bravo Collazo TM; Días de Villarvilla T; Machado Cano MJ; Bobés León MA Medwave; 2015 Apr; 15(3):e6112. PubMed ID: 25919584 [TBL] [Abstract][Full Text] [Related]
12. Interactive ERP recording increases the amplitude of the endogenous P300 peak in schizophrenia. Price GW Schizophr Res; 2000 Feb; 41(3):463-72. PubMed ID: 10728723 [TBL] [Abstract][Full Text] [Related]
13. Evidence-based medicine and electrophysiology in schizophrenia. Galderisi S; Mucci A; Volpe U; Boutros N Clin EEG Neurosci; 2009 Apr; 40(2):62-77. PubMed ID: 19534300 [TBL] [Abstract][Full Text] [Related]
14. Event-related potentials and genetic risk for schizophrenia. Winterer G; Egan MF; Rädler T; Coppola R; Weinberger DR Biol Psychiatry; 2001 Sep; 50(6):407-17. PubMed ID: 11566157 [TBL] [Abstract][Full Text] [Related]
15. N100 and P300 amplitude to Go and No-Go variants of the auditory oddball in siblings discordant for schizophrenia. Sumich A; Kumari V; Dodd P; Ettinger U; Hughes C; Zachariah E; Sharma T Schizophr Res; 2008 Jan; 98(1-3):265-77. PubMed ID: 18022352 [TBL] [Abstract][Full Text] [Related]
17. Auditory P300 amplitude as a state marker for positive symptoms in schizophrenia: cross-sectional and retrospective longitudinal studies. Higashima M; Nagasawa T; Kawasaki Y; Oka T; Sakai N; Tsukada T; Koshino Y Schizophr Res; 2003 Feb; 59(2-3):147-57. PubMed ID: 12414071 [TBL] [Abstract][Full Text] [Related]
18. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia]. Asato N; Hirayasu Y; Hiramatsu K; Ohta H Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977 [TBL] [Abstract][Full Text] [Related]
19. What do ERPs and ERFs reveal about the effect of antipsychotic treatment on cognition in schizophrenia? Korostenskaja M; Kähkönen S Curr Pharm Des; 2009; 15(22):2573-93. PubMed ID: 19689329 [TBL] [Abstract][Full Text] [Related]